Rubius Therapeutics, Inc. (RUBY)
(Delayed Data from NSDQ)
$15.55 USD
-0.23 (-1.46%)
Updated May 3, 2019 04:00 PM ET
After-Market: $15.53 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$15.55 USD
-0.23 (-1.46%)
Updated May 3, 2019 04:00 PM ET
After-Market: $15.53 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Rubius Therapeutics, Inc. (RUBY) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Rubius Therapeutics, Inc. (RUBY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Is a Surprise Coming for Rubius Therapeutics (RUBY) This Earnings Season?
by Zacks Equity Research
Rubius Therapeutics (RUBY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Should You Buy Rubius Therapeutics (RUBY) Ahead of Earnings?
by Zacks Equity Research
Rubius Therapeutics (RUBY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
5 Drug/Biotech Stocks Set to Outpace Q2 Earnings Estimates
by Kinjel Shah
Let us take a look at some drug/biotech stocks - FSTX, HALO, KNTE, RUBY and SPRB - that are poised to beat on second-quarter earnings.
The Zacks Analyst Blog Highlights: BioNTech, Ocugen, Rubius Therapeutics and Entera Bio
by Zacks Equity Research
The Zacks Analyst Blog Highlights: BioNTech, Ocugen, Rubius Therapeutics and Entera Bio
4 Biotech Stocks That Have Already Doubled This Year So Far
by Kinjel Shah
Stocks of BioNTech (BNTX), Ocugen (OCGN), Rubius Therapeutics (RUBY) and Entera Bio (ENTX) are up more than 100% this year so far.
Implied Volatility Surging for Rubius Therapeutics (RUBY) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Rubius Therapeutics (RUBY) stock based on the movements in the options market lately.
Company News for Mar 16, 2021
by Zacks Equity Research
Companies in the news are: RUBY, SJR, GNMK, RMBL
BioMarin (BMRN) Beats on Q1 Earnings, Lowers Sales View
by Zacks Equity Research
BioMarin (BMRN) beats estimates for both earnings and sales in the first quarter. It lowers its total revenue outlook for the year due to the potential impact of coronavirus outbreak.
BioMarin to Begin Early-Stage Study on Gene Therapy for PKU
by Zacks Equity Research
BioMarin (BMRN) is set to initiate dosing in an early-stage clinical study in the first quarter to evaluate its gene therapy candidate, BMN 307, in phenylketonuria, a rare disease affecting the brain.
Rubius (RUBY) in Focus: Stock Moves 8.7% Higher
by Zacks Equity Research
Rubius (RUBY) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.